Wolfgang Landgraf
C/o Oskar Helene Park 33
Berlin, BE 14195, Germany
Berlin, BE 14195, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
Importance of targeting post-prandial hyperglycaemia to achieve HbA1c goals in insulin glargine-treated subphenotypes of type 2 diabetes.
Journal: Diabetes, obesity & metabolism
Published: September 23, 2025
Responses to Basal Insulin Glargine (300 U/mL and 100 U/mL) with or Without Pre-prandial Insulin in Pre-treated Subphenotypes of Type 2 Diabetes: Insights from a Post Hoc Analysis.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: May 07, 2024
Treatment responses to basal insulin glargine 300 U/ml and glargine 100 U/ml in newly defined subphenotypes of type 2 diabetes: A post hoc analysis of the EDITION 3 randomized clinical trial.
Journal: Diabetes, obesity & metabolism
Published: August 01, 2023
Response to insulin glargine 100 U/mL treatment in newly-defined subgroups of type 2 diabetes: Post hoc pooled analysis of insulin-naïve participants from nine randomised clinical trials.
Journal: Primary care diabetes
Published: January 17, 2023
Comparative efficacy and safety of Gla-300 versus IDegAsp in insulin-naïve people with type 2 diabetes mellitus uncontrolled on oral anti-diabetics.
Journal: Diabetes, obesity & metabolism
Published: December 22, 2022
Distribution and characteristics of newly-defined subgroups of type 2 diabetes in randomised clinical trials: Post hoc cluster assignment analysis of over 12,000 study participants.
Journal: Diabetes research and clinical practice
Published: June 09, 2022
Hypoglycaemia risk with insulin glargine 300 U/mL compared with glargine 100 U/mL across different baseline fasting C-peptide levels in insulin-naïve people with type 2 diabetes: A post hoc analysis of the EDITION 3 trial.
Journal: Diabetes, obesity & metabolism
Published: February 16, 2020
Fasting C-peptide, a biomarker for hypoglycaemia risk in insulin-naïve people with type 2 diabetes initiating basal insulin glargine 100 U/mL.
Journal: Diabetes, obesity & metabolism
Published: July 30, 2019
Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0.
Journal: Diabetes, obesity & metabolism
Published: April 25, 2018
Hypoglycaemia risk in the first 8 weeks of titration with insulin glargine 100 U/mL in previously insulin-naive individuals with type 2 diabetes mellitus.
Journal: Diabetes, obesity & metabolism
Published: January 02, 2018
Glycaemic responses in Asian and non-Asian people with type 2 diabetes initiating insulin glargine 100 units/mL: A patient-level pooled analysis of 16 randomised controlled trials.
Journal: Diabetes research and clinical practice
Published: June 02, 2017
The use of lipid-lowering therapy and effects of antihyperglycaemic therapy on lipids in subjects with type 2 diabetes with or without cardiovascular disease: a pooled analysis of data from eleven randomized trials with insulin glargine 100 U/mL.
Journal: Cardiovascular diabetology
Published: February 15, 2017
Last Updated: 09/26/2026